TTP399: First-Ever Pill Therapy for Type 1 Diabetes? was reported by Mike Hoskins for DiabetesMine.com, 3 August 2020.
Currently under development by North Carolina-based pharmaceutical company vTv Therapeutics, this future medication is called TTP399. That’s an investigational-stage moniker that will eventually be replaced with a snappier brand name.
If it makes it to market, vTv suggests that this daily pill, taken alongside insulin, could mean lower A1C levels, more glucose time in range (TIR) without risk of increased hypo or hyperglycemia (dangerously high or low blood sugars), decreased insulin needs, and no side effects that often accompany add-on medications promising better blood sugars.
Exercise immediately after insulin dosing ‘unsafe’: Pilot study was reported by Regina Schaffer for Healio.com/News/Endocrinology, 31 July 2020.
A low insulin level coupled with euglycemia or modest hyperglycemia are the most favorable conditions for exercise for people with type 1 diabetes, findings from a small pilot study suggest.
“It is unsafe to exercise shortly after taking a dose of insulin,” Rita Basu, MD, professor of medicine in the division of endocrinology and clinical education director of the Center for Diabetes Technology at the University of Virginia School of Medicine, told Healio. “Moderate exercise in people with type 1 diabetes to maintain active lifestyle is preferred when their blood glucose levels are normal or modestly elevated, but not when their circulating insulin concentrations are raised, such as shortly after a bolus or prandial dose of insulin.”